Madrigal Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals

Conshohocken, pa., april 24, 2024 (globe newswire) -- the madrigal team is shocked and saddened to learn of the passing of dr. stephen harrison.

Conshohocken, pa., april 16, 2024 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (nash), today announced that the company granted equity awards to 7 new employees, in each case with a grant date of april 15, 2024, as equity inducement awards under the terms of the company's 2023 inducement plan. the equity awards were approved in accordance with nasdaq listing rule 5635(c)(4).

Conshohocken, pa., april 03, 2024 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (nash), today announced that the company granted equity awards to 30 new employees, in each case with a grant date of april, 1 2024, as equity inducement awards under the terms of the company's 2023 inducement plan. the equity awards were approved in accordance with nasdaq listing rule 5635(c)(4).

Conshohocken, pa., march 18, 2024 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq: mdgl), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (nash), today announced the pricing of its underwritten public offering of 750,000 shares of its common stock at a public offering price of $260.0000 per share, and, to certain investors, pre-funded warrants to purchase 1,557,692 shares of common stock at a price of $259.9999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. the size of the offering was increased by $100 million subsequent to the initial announcement of the offering...

Conshohocken, pa., march 18, 2024 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq: mdgl), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (nash), today announced that it has commenced an underwritten public offering of $500 million in shares of its common stock and pre-funded warrants to purchase common stock. the purchase price of each pre-funded warrant will equal the price per share at which shares of common stock are being sold to the public in this offering, minus $0.0001, which will be the per share exercise price of each pre-funded warrant. madrigal also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions...

Madrigal Pharmaceuticals just commercialized its first medicine. Viking Therapeutics has a mid-stage candidate with great potential.

Madrigal Pharmaceuticals scored a historical regulatory approval last month. Even so, the market has been taking a cautious approach to Madrigal's shares.

Right now, biotech is one of the hottest sectors on the market, creating big opportunities for some of the best biotech stocks to buy in April. All of this is thanks to new innovation, millions of retiring baby boomers, demand for better care, pharmaceutical companies nearing patent expirations, a resurgence of mergers and acquisitions, and even new treatments that'll help you shed weight.

Viking's drug candidate has shown promise in clinical studies as a potential weight loss medicine. Madrigal just launched the first (and so far only) medicine approved by the U.S. for NASH.

The Food and Drug Administration recently granted accelerated approval for Rezdiffra, a potential blockbuster for Madrigal Pharmaceuticals. At its peak, the drug could bring in more than $5 billion in revenue per year.

After a strong resurgence in the back half of 2023 and continued momentum into the first quarter of 2024, biotech stocks are back in vogue. “Hawkish” Federal Reserve Policy, a brutal bear market in 2022, and investor preference for big tech stocks have meant underperformance for biotech stocks.

Madrigal earned the first approval for a medicine in an area with a high unmet need. The commercial opportunity for this therapy, which treats a liver disease, looks exciting.

Last week's FDA approval of Rezdiffra in treating NASH is a huge milestone for Madrigal. Lilly and Novo Nordisk look much more impressive than Madrigal in most ways.

Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.

On March 14, Madrigal Pharmaceuticals, Inc. announced that the FDA has granted accelerated approval for Rezdiffra, for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis. This accelerated approval makes Rezdiffra the first and only FDA-approved NASH treatment, which will become available in April 2024 in the US. I discuss Madrigal Pharmaceutical as an investment opportunity in this article.